2022 Global Healthcare Conference
Tuesday, September 13 – Wednesday, September 14
INTERCONTINENTAL NEW YORK BARCLAY

enOvis

Matt Trerotola
CEO

Chris Hix
CFO
FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, including the anticipated benefits of the separation of Enovis’ fabrication technology and specialty medical technology businesses (the “Separation”) and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the scope and duration of the outbreak, the rise, prevalence and severity of variants of the virus, material delays and cancellations of medical procedures, the nature and effectiveness of actions and restrictive measures by governments, businesses and individuals in response to the situation, and their impact on the global and regional economies, financial markets, creditworthiness and financial viability of customers, and overall demand for our products; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; the potential to incur significant liability if the Separation is determined to be a taxable transaction or the remaining portion of our investment in ESAB Corporation is monetized in a taxable manner; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the company following the Separation; volatility associated with ESAB Corporation’s share price and the related value of our investment in ESAB Corporation; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

NON-GAAP FINANCIAL MEASURES

This presentation includes a forward-looking projection of adjusted EBITDA, a financial measure that is not calculated in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"), which Enovis uses to measure the performance of its business. Adjusted EBITDA represents operating income from continuing operations excluding restructuring and other related charges, MDR and related costs, strategic transaction costs, stock-based compensation costs, depreciation and amortization, amortization of acquired intangibles, insurance settlement gain, and inventory step up costs. The non-GAAP financial measures provided herein should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. A reconciliation of adjusted EBITDA to the closest GAAP financial measure is not available without unreasonable efforts on a forward-looking basis due to the impact and timing on future operating results arising from items excluded from this measure.
Well-Positioned in Large, Attractive Ortho Market

2022 Outlook

Sales

$1.6B

aEBITDA

$235-255mm

Sales by Geography and Segment

- United States 68%
- Europe 27%
- ROW 5%

Enovis competes in half of the $53B Orthopedics market and “touches” nearly all

<table>
<thead>
<tr>
<th>Market CAGR</th>
<th>Knee</th>
<th>Hip</th>
<th>Extremities</th>
<th>Trauma</th>
<th>Sports Medicine</th>
<th>Spine</th>
<th>Biologics</th>
</tr>
</thead>
<tbody>
<tr>
<td>$5B (~4%)</td>
<td>9</td>
<td>8</td>
<td>3</td>
<td>7</td>
<td>6</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>$48B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Our Recon served markets

<table>
<thead>
<tr>
<th>Our Recon served markets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Implants and Instrumentation</td>
</tr>
<tr>
<td>Prevention &amp; Rehabilitation (P&amp;R)</td>
</tr>
</tbody>
</table>

Enovis has sustainable capabilities to outgrow its markets
### Prevention & Recovery Segment

- Industry-defining products **across Orthopedics**
- Leader in fast growing **Sports Medicine** segment
- MotionMD® workflow software solution **drives 45% of US Clinics**
- **Strong International Position:** 32% ex-US Sales

### Reconstructive Segment

- Track record of **double-digit growth** in Shoulder, Hip and Knee
- ~50% of Recon platform in **high growth extremities segments**
- A **global leader in Shoulder** (Reverse, Stemless anatomic)
- Sustained share gain in large US Hip/Knee segments
- Innovative and expanding Foot & Ankle portfolio

### #1
- **Globally in Bracing**
  - DonJoy®
- **Globally in Rehab**
  - Aircast®
- **In Bone Stimulation**
  - Chattanooga®
  - LiteCure®

### #2
- **In Bone Stimulation**
  - Altivate®

### DD
- **Organic Growth**
- **30% Sustained vitality**
- **+23% New surgeons ($100K+) since 2018**

### Empowr
- **Dual Mobility™**
- **Empowr®

---

Established brands and accelerating innovation across our businesses
Agile Innovator in Fragmented Industry

**Competitive Ortho Landscape**

**Ortho Revenue**

- **>$3B**
  - Big, broad majors
- **$0.5 - $3B**
  - Scaled, differentiated players
- **< $0.5B**
  - Focused innovators

~30 players in $0.1-0.5B range
~1,000 pre-revenue or early revenue players

**Enovis’ Attractive Position**

- Big enough for healthy margins but additional room to scale
- Small enough to operate like an innovator
- Can select most valuable growth paths
- Ample bolt-on opportunities, attractive path to market/scale for innovators

Enovis positioned for share gain, scale and strategic investment
Innovation Investments Driving Core Growth

**P&R: Enhancing Leadership Position**

- **Modernizing Core segments**
- **Expanding into high growth categories**
- **Leading transition to modalities**
- **Pioneering Connected Medicine MotionIQ™**

**Recon: Market-Leading Innovation Cadence**

- **Breadth** in key shoulder franchise
- **Extending** Empowr® Knee impact across treatment protocol
- **Advancing modern hip implant systems**
- **Simplifying workflows for ASC** and improving guidance/precision

Pipeline of innovation supports sustainable HSD organic growth path
M&A Execution Enhancing Growth Profile

- **Accelerating our growth**: achieved double-digit pro forma organic sales growth in 1H22
- **Increasing our margin opportunity**: acquisitions have mid-60’s adj. gross margin, above Company average
- **Great integration progress**
  - Launched Empowr 3D Knee® & AltiVate Reverse® into Mathys sales channel
  - Launched new Foot & Ankle products: DynaNail® Helix and Arsenal Ankle Plating System™
  - Cost synergies at Mathys on track to reach $15mm run-rate in 2024
  - Initiated commercial launch of ARVIS®

Balance sheet and expected cash flow create $1B near-term investment capacity
Realizing Our Vision: High-Value Med-Tech Growth

Enovis Sales Performance Goals

- **P&R**
- **Recon**
- **New**

2022E
- ~$1.6B
  - Improve and shape P&R
- Aggressively grow and expand Recon

2024 Goal
- ~$2.0B
  - Enter adjacent high-growth segments
  - Scale Recon
  - Extend P&R leadership

Future Goal

3-Year Goals

- **HSD**
  - Organic Revenue Growth
  - ~20% aEBITDA Margin
  - $2B+ Annual Sales

Taking meaningful steps on a clear path toward our strategic goals
Q&A